Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of Lu-177-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)-First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).